Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 02, 2007 3:53pm
224 Views
Post# 13742966

RE: clarification

RE: clarification
Kev...   my understanding is that PLI has already given BLOOD the results of the trials under a confidentiality agreement.   In fact,  the results were submitted to the ASH / Blood panel for screening / acceptance into the conference,  then the results are "embargoed".

As part of the agreement,   the Scientific Results will then be released in the December issue of BLOOD Magazine,  by BLOOD Magazine (not PLI) when the December issue comes out.  ( expected Nov 14th - 21st week )  The full Clinical result presentation will then be conducted by Prometic at the ASH Annual Meeting in December.

Bullboard Posts